Margarida Maia, PhD, science writer —

People with ANCA-associated vasculitis (AAV) may present different lung involvement patterns depending on the type of disease and self-reactive antibodies driving the disease, according to a small study. Given that “the type of pulmonary involvement in AAV is important to predict prognosis and mortality as well as for treatment…

A low dose of intravenous or into-the-vein methylprednisolone, a corticosteroid, is as safe and effective as a high dose at preserving kidney function and extending survival in people with severe ANCA-associated vasculitis (AAV), a U.K. study found. Given that corticosteroids, a standard AAV treatment, are associated with significant…

A protein fragment called Ba that’s produced when the alternative complement pathway is activated is found at high levels in the urine of people with ANCA-associated vasculitis (AAV) during a kidney flare, a small study suggests. This means it may serve as a biomarker for predicting and monitoring kidney-related…

AstraZeneca’s Fasenra (benralizumab) — approved for a rare type of asthma — does no worse than Nucala (mepolizumab) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. These are the first findings of the head-to-head Phase 3 MANDARA clinical trial (NCT04157348) that showed the study met its…

Microscopic polyangiitis (MPA) was the most common type of ANCA-associated vasculitis (AAV) among girls and Hispanic children in a California tertiary care hospital, a small study has found. While time to diagnosis was shorter, children with the disorder seemed to need more intensive care and dialysis, a treatment that…

An approach that removes specific antibodies from a person’s blood is better than a standard, more general blood-cleaning procedure called plasma exchange at clearing the self-reactive antibodies that drive ANCA-associated vasculitis (AAV). That’s according to a small study in China that looked at data from AAV patients with severe…

People with ANCA-associated vasculitis (AAV) often face a high medication burden — managing multiple medications, also known as polypharmacy — with most patients covered by Medicare on five or more treatments at the same time in the first year after their diagnosis, a study found. Among the factors…

Blood levels of globulins — a group of proteins that includes antibodies — when ANCA-associated vasculitis (AAV) is diagnosed can help in forecasting the risk of a patient dying of any cause, a large data study from Korea suggests. “The present study is the first to demonstrate that [total…

Treatment with Tavneos (avacopan) results in significant and clinically meaningful improvements in health-related quality of life (HRQoL) for people with ANCA-associated vasculitis (AAV), according to findings from the Phase 3 ADVOCATE clinical trial. “The ADVOCATE study is, to our knowledge, the first trial in patients with ANCA-associated vasculitis…

Dosing has begun in a Phase 2 clinical trial of imlifidase, an  antibody-cleaving therapy, in people with ANCA-associated vasculitis (AAV) who have or are at risk of disease-associated acute respiratory distress syndrome (ARDS), Hansa Biopharma, the therapy’s developer, announced. ARDS, a severe complication of AAV, occurs…